VSJ-110
/ Vanda
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 18, 2025
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
(clinicaltrials.gov)
- P2 | N=160 | Recruiting | Sponsor: Vanda Pharmaceuticals
New P2 trial • Dry Eye Disease • Ophthalmology
March 06, 2024
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: Vanda Pharmaceuticals
New P2 trial • Dry Eye Disease • Ophthalmology
April 27, 2022
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
(clinicaltrials.gov)
- P2 | N=41 | Completed | Sponsor: Vanda Pharmaceuticals | Recruiting ➔ Completed | Trial primary completion date: Jan 2021 ➔ May 2021
Trial completion • Trial primary completion date • Allergy • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology
1 to 3
Of
3
Go to page
1